Rituximab Treatment in Myasthaenia Gravis Report of two paediatric cases

Rituximab Treatment in Myasthaenia Gravis Report of two paediatric cases


Subject and more

  • LCC Subject Category: Biochemistry, Biomedicine, Medicine
  • Publisher's keywords: Myasthenia Gravis; Rituximab; Children; Cholinergic Receptors; Case Report; Oman
  • Language of fulltext: english
  • Full-text formats available: PDF


    Roshan Koul, Amna Al-Futaisi, Rana Abdelrahim, Renjith Mani, Reem Abdwani, Abdullah Al-Asmi



To download PDF files Login to your Account.


Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction. Te condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and signifcant clinical improvement in the other case.

About Europub

EuroPub is a comprehensive, multipurpose database covering scholarly literature, with indexed records from active, authoritative journals, and indexes articles from journals all over the world. The result is an exhaustive database that assists research in every field. Easy access to a vast database at one place, reduces searching and data reviewing time considerably and helps authors in preparing new articles to a great extent. EuroPub aims at increasing the visibility of open access scholarly journals, thereby promoting their increased usage and impact.